Anticancer approach by targeted activation of a global inhibitor of sialyltransferases with acrolein

Takatsugu Kasahara,Tsung-Che Chang,Hiromasa Yoshioka,Sayaka Urano,Yasuko Egawa,Michiko Inoue,Tsuyoshi Tahara,Koji Morimoto,Ambara R. Pradipta,Katsunori Tanaka

DOI: https://doi.org/10.1039/d4sc00969j

IF: 8.4

2024-05-26

Chemical Science

Abstract:Cells are covered with a thick layer of sugar molecules known as glycans. Abnormal glycosylation is a hallmark of cancer, and hypersialylation increases tumor metastasis by promoting immune evasion and inducing tumor cell invasion and migration. Inhibiting sialylation is thus a potential anticancer treatment strategy. However, targeting sialic acids is difficult because of the lack of selective delivery tools. Here, we present a prodrug strategy for selectively releasing the global inhibitor of sialylation peracetylated 3F ax -Neu5Ac (PFN) in cancer cells using the reaction between phenyl azide and endogenous acrolein, which is overproduced in most cancer cells. The prodrug significantly suppressed tumor growth in mice as effectively as PFN without causing kidney dysfunction, which is associated with PFN. The use of sialylated glycans as immune checkpoints is gaining increasing attention, and the proposed method for precisely targeting aberrant sialylation provides a novel avenue for expanding current cancer treatments.

chemistry, multidisciplinary